| HS Code | 395699 |
| Product Name | HYRUAN Plus Inj. |
| Active Ingredient | Sodium Hyaluronate |
| Concentration | 1% (10 mg/mL) |
| Formulation | Injectable solution |
| Indication | Osteoarthritis of the knee |
| Administration Route | Intra-articular injection |
| Volume Per Syringe | 2 mL |
| Storage Temperature | 2°C to 25°C |
| Manufacturer | LG Chem |
| Country Of Origin | South Korea |
| Prescription Status | Prescription only |
| Appearance | Clear, colorless, viscous solution |
| Sterilization | Sterile, single-use syringe |
| Osmolarity | Approximately 270~400 mOsm/kg |
| Ph | 6.8~7.8 |
As an accredited HYRUAN Plus Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | HYRUAN Plus Inj. packaging features a white and purple box, labeled “2 mL × 1 syringe,” clearly displaying product and dosage. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) for HYRUAN Plus Inj.: Typically accommodates around 70,000–80,000 syringes, securely packaged for international pharmaceutical transport. |
| Shipping | HYRUAN Plus Inj. should be shipped in its original packaging, protected from sunlight, moisture, and extreme temperatures. Transport at 2–25°C to ensure product stability. Handle with care, adhering to all relevant chemical and pharmaceutical shipping regulations. Ensure prompt delivery to maintain product efficacy and integrity. |
| Storage | **HYRUAN Plus Inj.** should be stored in a cool, dry place, protected from light, at a temperature between 2°C and 25°C (36°F and 77°F). Keep the injection in its original packaging until use to avoid contamination. Do not freeze. Ensure it is kept out of reach of children and is not used after the expiration date. |
| Shelf Life | HYRUAN Plus Inj. has a shelf life of 24 months from the manufacturing date when stored at room temperature below 25°C. |
HYRUAN Plus Inj., produced in our GMP-compliant facility, is a high-purity, injectable-grade hyaluronic acid that supports critical functions in various regulated sectors. The following application scenarios demonstrate real downstream industrial uses where the raw material directly advances specific product quality and process standards.
Pharmaceutical manufacturers incorporate HYRUAN Plus Inj. as a viscosupplement in intra-articular injection products for knee osteoarthritis therapy. The precise molecular weight and purity profile enable formulation of sterile injectable solutions meeting stringent safety and biocompatibility requirements. Injectable HA operates as a synovial fluid substitute, supporting joint lubrication and cushioning during physical activity. Operators hydrate and dissolve the material in WFI (Water for Injection), followed by sterile filtration and aseptic filling into pre-sterilized vials or syringes.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Ophthalmic suppliers use HYRUAN Plus Inj. as the principal viscoelastic agent for surgical aids during cataract procedures, glaucoma interventions, and corneal transplants. The ingredient provides tissue protection, space maintenance, and cell shielding within the anterior chamber. The downstream process addresses strict endotoxin and particulate limits, involving solution preparation in Class 100 cleanrooms and terminal sterilization or aseptic filling, depending on the device registration.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Medical aesthetics manufacturers integrate our injectable hyaluronic acid as the matrix for advanced dermal filler products. Crosslinking reactions utilize medical device-grade reagents to engineer gels with controlled modulus, supporting targeted wrinkle correction and facial volume restoration. The downstream processes operate in strictly controlled clean environments using low-endotoxin specifications and precise gel sizing/sterilization protocols.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Biomedical companies select our ingredient as the hydrating polymer base for anti-adhesion products installed during abdominal, pelvic, and spinal surgery. The hydrated polysaccharide gel forms a temporary, bioresorbable barrier that physically separates tissues during critical healing phases, limiting fibrous adhesion formation without impairing natural tissue repair. Quality assurance focuses on maintaining ultra-low residual protein and DNA content.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Animal health and veterinary drug manufacturers deploy this injectable hyaluronate for high-value intra-articular lubricants and veterinary ocular devices. Veterinary formulations demand similar sterility and viscosity as human-use products, with adjustments for animal physiology and usage scenarios in equine and companion animal care. Processes replicate pharmaceutical-grade cleanroom protocols and emphasize absence of pyrogens and contaminants.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive HYRUAN Plus Inj. prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618018036652
Email: sales6@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
At our manufacturing site, the story behind HYRUAN Plus Inj. is more than a sequence of production steps or paperwork. After years of refining fermentation, purification, and formulation under carefully monitored conditions, we bring this product forward for use in joint therapy as a practical, effective option for physicians serious about outcome and patient comfort.
Every ampoule of HYRUAN Plus Inj. is a result of genuine hands-on involvement, right down to the molecular details. We use high-grade, non-animal stabilized hyaluronic acid at 1% concentration, specifically matching the needs for viscosupplementation in osteoarthritic knees. Our molecular weight falls around 3 million Daltons. This particular profile guides the body’s tissues toward proper lubrication, without introducing foreign protein fragments often seen in extracted animal-source formulations.
Anyone working at the intersection of production and medicine learns quickly that not all hyaluronic acid injections behave the same way. Market booths talk about purity and concentration, but we focus on consistent rheological properties, syringeability, and long-term shelf stability—details that physicians and nurses depend on with every injection. With its precise balance of crosslinking, HYRUAN Plus Inj. delivers both the initial cushioning effect and lasting lubrication, minimizing rapid enzymatic breakdown.
In practical situations, such as treating patients with moderate-to-severe knee osteoarthritis, this means fewer repeat procedures and more reliable improvement in joint function. Highly purified, non-immunogenic hyaluronic acid reduces the risk of local inflammatory responses, and every production batch undergoes strict endotoxin and protein residue checks, far exceeding local and international guidelines.
The comparison between in-house manufactured HYRUAN Plus Inj. and import products often comes down to transparency and reproducibility. Many products are blended from animal tendons or rooster combs, creating a variable molecular weight distribution and the chance of avian protein residue. We use microbial fermentation—bacterial strains that are under continuous quality control. We also maintain a closed-system production, reducing the likelihood of environmental contamination. In the hands of clinicians, this translates into predictable viscosupplement properties and a reduced incidence of pseudo-septic responses.
Unlike certain one-shot or multi-injection systems that either deliver a quick, short-lived relief or prolong discomfort with multiple visits, our formulation is engineered for single-injection convenience combined with appropriate residence time. Extensive feedback from users indicates both improved patient adherence and fewer treatment interruptions.
Quality is not a buzzword manufactured for the packaging. Our teams on the factory floor can trace each lot of sodium hyaluronate back to its fermentation tank. End-to-end oversight is not just an obligation—it’s how we preserve uniformity and confidence for every end-user. This vigilance proved especially crucial during raw material shortages and global supply disruptions, which prompted some other products to lower their controls or adjust components to fit what’s available. HYRUAN Plus Inj. remains consistent, with testing to confirm the absence of animal-derived DNA, viral contaminants, and undefined excipients before filling and sterilization.
Over the years, adverse reactions are rare, and every report, no matter how mild, feeds directly back to our on-site process improvement team. In real terms, that translates to safer injections and low incidence of post-injection synovitis or skin reactions that can be traced to protein impurities or foreign residues in competing formulations.
Doctors rely on clear, verifiable product data. We don’t just include IFU leaflets and certificates. Site visits, practical workshops, and physician feedback sessions are integrated into our approach. Questions about temperature excursions, re-sterilization, atypical patient responses, or off-label use are fielded directly by our technical team—not a faceless sales rep.
Over the years, our direct relationships with orthopedic and rehabilitation clinics have provided valuable insight. For example, we’ve integrated features that matter in the real world: a robust stopper system that prevents accidental leakage during transportation, color-coded labeling to prevent mix-ups, and an ergonomic syringe interface that allows for stable, accurate delivery even in fast-paced clinical settings.
Rising osteoarthritis rates—especially among aging populations and younger adults experiencing joint degradation—drive up the demand for reliable viscosupplementation. Synthetic corticosteroid regimes fail to offer structural protection and are increasingly scrutinized for bone and cartilage health impacts. Many clinicians now incorporate HYRUAN Plus Inj. as part of multimodal therapy, leveraging our data on safety and patient tolerability for both primary use and after unsuccessful alternatives.
Every year, we analyze usage and outcome data—not just in randomized clinical trials but in daily outpatient practice. Our plant’s pharmacovigilance teams study injection intervals, joint mobility outcomes, and patient-reported pain scores to continually inform our manufacturing strategy. In several multicenter studies, patients using our formulation showed improved WOMAC and Lequesne scores compared to baseline and, in some studies, to other hyaluronic acid injectables.
Drawing from tens of thousands of clinical uses, we noticed that users requested easier syringe manipulation and higher extrusion force. Using physician and nurse feedback, we adjusted the viscosity profile to provide a smoother, more consistent injection flow at body temperature—a point often missed by overseas suppliers who focus on cold-chain testing.
The transparency of our process allows every batch to be evaluated not just on in-lab metrics but also on user satisfaction and patient outcomes. If even a handful of users express concern about stopper residue or particulate formation, we immediately escalate investigations back to procurement, ensuring purity in every step from water-for-injection to terminal sterilization.
From the earliest planning phases, our site committed to responsible use of feedstocks, energy, and water. By producing hyaluronic acid through fermentation methods, we sidestep many risks and environmental costs associated with slaughterhouse byproducts. Waste effluents, microbial residues, and even disposable syringes undergo responsible treatment or recycling where possible.
Our local community health outreach programs are not a marketing gesture—they reflect the same attitude shown in our manufacturing lines: doing the work properly, sharing our knowledge with nearby clinics, and raising the overall bar for pharmaceutical-quality injectable products.
Each regulatory filing is the result of thousands of hours of cross-checks and communication with health authorities. Every batch of HYRUAN Plus Inj. passes strict limits for endotoxins, residual solvents, and DNA content. The commitment to full transparency means all product data sheets, clinical studies, and traceability documents are available for authorities and registered clinics, not buried behind multinational legal departments.
Feedback from periodic audits is channeled directly into our change control system. User requests for packaging improvements, clear expiration dating, and tamper-evidence are given the same respect as lab assay results. This shared responsibility—linking manufacturer, distributor, physician, and patient—shapes safer, more effective therapies on every shipment.
The increased global demand for viscosupplementation creates pressure to cut corners. We have watched suppliers elsewhere decrease fermentation cycle times to boost output or bypass full molecular characterization. At our facility, we refuse these shortcuts. Stable, high-molecular, and high-purity hyaluronic acid takes time, careful monitoring, and an experienced hand. We regularly reinvest profits into technology upgrades for bioreactors, ultrafiltration units, and final fill-finish machinery.
Maintaining consistent quality across thousands of doses per day, under strict cleanliness and with absolute sterility, requires a level of dedication seldom appreciated outside manufacturing circles. Our commitment is visible in every syringe that leaves our site—backed by batch-to-batch certification and a persistent drive to eliminate avoidable risk at source.
Osteoarthritis trends don’t rest, so neither does our research team. We are currently evaluating new crosslinked derivatives to prolong residence time for specific patient groups, and studying next-generation devices to further reduce injection pain and post-procedure swelling. Collaborations with leading medical institutions are examining potential uses beyond the knee—such as small-joint viscosupplementation and adjunct therapy in orthopedic surgery recovery.
The future of injectable hyaluronic acid lies not in grand advertising but in transparent, continuous dialogue between those who manufacture and those who use these products on patients who trust their care teams. With HYRUAN Plus Inj., our promise stands: maintain the quality, improve whenever possible, and put every lesson of experience back into the cycle so that every user—from the nurse loading the syringe to the patient walking out of the clinic—benefits from the integrity at the heart of its manufacture.